Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene

Lin, Junyang; Liu, Tsang-Pai; Andriani, Vivin; Athoillah, Muhammad; Wang, Chih‐Yang; Yang, Pei–Ming

doi:10.3390/jpm11111199

Cited by 4 publications

(3 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By identifying a gene signature from the transcriptome of HCC patients functionally related to mitotic cell cycle regulation, Lin et al demonstrated the sensitivity of HCC lines with mutant TP53 or wild-type CTNNB1 genes to taxanes using gene-drug association analysis. As a result, the study suggested a benefit of treatment with paclitaxel in this patient population [68]. A poor prognosis-associated signature was identified by Yang et al in patients with the TP53 mutation; subsequently, in silico screening of three targets (CANT1, CBFB, and PKM) and two agents (irinotecan and YM-155) were noted to have a potential therapeutic impact on patients with a poor prognosis-associated signature [69].…”

Section: Pt53mentioning

confidence: 79%

Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma

Gorji,

Brown,

Pawlik

2023

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fourth most common malignancy worldwide and exhibits a universal burden as the incidence of the disease continues to rise. In addition to curative-intent therapies such as liver resection and transplantation, locoregional and systemic therapy options also exist. However, existing treatments carry a dismal prognosis, often plagued with high recurrence and mortality. For this reason, understanding the tumor microenvironment and mutational pathophysiology has become the center of investigation for disease control. The use of precision medicine and genetic analysis can supplement current treatment modalities to promote individualized management of HCC. In the search for personalized medicine, tools such as next-generation sequencing have been used to identify unique tumor mutations and improve targeted therapies. Furthermore, investigations are underway for specific HCC biomarkers to augment the diagnosis of malignancy, the prediction of whether the tumor environment is amenable to available therapies, the surveillance of treatment response, the monitoring for disease recurrence, and even the identification of novel therapeutic opportunities. Understanding the mutational landscape and biomarkers of the disease is imperative for tailored management of the malignancy. In this review, we summarize the molecular targets of HCC and discuss the current role of precision medicine in the treatment of HCC.

show abstract

Section: Pt53mentioning

confidence: 79%

Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma

Gorji,

Brown,

Pawlik

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…HCC is one of the most common malignant tumors in the world, and with the continuous development of medical technology and research on the molecular biology of tumors, targeted therapy for hepatocellular carcinoma is developing rapidly [1,2]. TERT, MLL4, CCNE1, TP53, and CTNNB1 were identified as commonly mutated genes in HCC [26][27][28][29][30]. Despite the availability of many potential therapeutic targets, the incidence and mortality rates of patients with HCC are still increasing currently [8][9][10][11].…”

Section: Discussionmentioning

confidence: 99%

LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis

Wang

Yang

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) is aggressive cancer with a poor prognosis. It has been suggested that the aberrant expression of LOXL2 is associated with the development of HCC, but the exact mechanism remains unclear. This research is aimed at examining the expression level and prognostic value of LOXL2 in hepatocellular carcinoma and its relationship with immune infiltration and at predicting its upstream noncoding RNAs (ncRNAs). Method. The transcriptome data of HCC was first downloaded from The Cancer Genome Atlas (TCGA) database to investigate the expression and prognosis of LOXL2. Then, the starBase database was used to find the upstream ncRNAs of LOXL2, and correlation analysis and expression analysis were performed. Finally, the Tumor Immune Estimation Resource (TIMER) was used to explore the association between LOXL2 and immune cell infiltration. Result. CARMN was considered to be the potential upstream lncRNA for the hsa-miR-192-5p/LOXL2 axis in HCC. Furthermore, the level LOXL2 was markedly positively associated with tumor immune cell infiltration and immune checkpoint expression in HCC. Conclusion. Higher expression of LOXL2 mediated by microRNA (miRNA) and long noncoding RNAs (lncRNA) is associated with poor overall survival (OS), immune infiltration, and immune checkpoint expression in HCC.

show abstract

“…Inhibition of glutamine metabolism improves sorafenib Chemosensitization in oxoglutarate dehydrogenase-like (OGDHL)-defcient hepatoma cells [66]. Decreased glutamine synthesis results in growth inhibition of CTNNB1-mutated HCC xenografts by a combination of glutamine synthetase inhibitors and asparaginase inhibitors [67,68].…”

Section: Amino Acid Based Metabolic Biomarkersmentioning

confidence: 99%

Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma

Xie

Zhang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Primary liver carcinoma is the sixth most common cancer worldwide, while hepatocellular carcinoma (HCC) is the most dominant cancer type. Chronic hepatitis B and C virus infections and aflatoxin exposure are the main risk factors, while nonalcoholic fatty liver disease caused by obesity, diabetes, and metabolic syndrome are the more common risk factors for HCC. Metabolic disorders caused by these high-risk factors are closely related to the tumor microenvironment of HCC, revealing a possible cause-and-effect relationship between the two. These metabolic disorders involve many complex metabolic pathways, such as carbohydrate, lipid, lipid derivative, amino acid, and amino acid derivative metabolic processes. The resulting metabolites with significant abnormal changes in the concentration level in circulating blood may be used as biomarkers to guide the diagnosis, treatment, or prognosis of HCC. At present, there are high-throughput technologies that can quickly detect small molecular metabolites in many samples. Compared to tissue biopsy, blood samples are easier to obtain, and patients’ willingness to participate is higher, which makes it possible to study blood HCC biomarkers. Over the past few years, a substantial body of research has been performed worldwide, and other potential biomarkers have been identified. Unfortunately, due to the limitations of each study, only a few markers have been widely verified and are suitable for clinical use. This review briefly summarizes the potential blood metabolic markers related to the diagnosis of HCC, mainly focusing on amino acids and their derivative metabolism, lipids and their derivative metabolism, and other possible related metabolisms.

show abstract

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene

Cited by 4 publications

References 61 publications

Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma

Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma

LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis

Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma

Contact Info

Product

Resources

About